FDA approves 1st targeted HER2-low breast cancer therapy

By Becker's Hospital Review - Healthcare News in Becker's Hospital Review, Channels, Featured
August 5, 2022

The FDA approved Enhertu Aug. 6, the first targeted therapy for HER2-low breast cancer.

Read the full post on Becker's Hospital Review - Healthcare News

Becker's Hospital Review - Healthcare News